Abstract
Organic cation transporters (OCTs) of the solute carrier family (SLC) 22 and multidrug and toxin extrusion (MATE) transporters of the SLC47 family have been identified as uptake and efflux transporters, respectively, for xenobiotics including several clinically used drugs such as the antidiabetic agent metformin, the antiviral agent lamivudine, and the anticancer drug oxaliplatin. Expression of human OCT1 (SLC22A1) and OCT2 (SLC22A2) is highly restricted to the liver and kidney, respectively. By contrast, OCT3 (SLC22A3) is more widely distributed. MATEs (SLC47A1, SLC47A2) are predominantly expressed in human kidney. Data on in vitro studies reporting a large number of substrates and inhibitors of OCTs and MATEs are systematically summarized. Several genetic variants of human OCTs and in part of MATE1 have been reported, and some of them result in reduced in vitro transport activity corroborating data from studies with knockout mice. A comprehensive overview is given on currently known genotype–phenotype correlations for variants in OCTs and MATE1 related to protein expression, pharmacokinetics/-dynamics of transporter substrates, treatment outcome, and disease susceptibility.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abel S, Nichols DJ, Brearley CJ, Eve MD (2000) Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide. Br J Clin Pharmacol 49:64–71
Abramson J, Smirnova I, Kasho V, Verner G, Kaback HR, Iwata S (2003) Structure and mechanism of the lactose permease of Escherichia coli. Science 301:610–615
Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P et al (2008) Structural requirements for drug inhibition of the liver specific human organic cation transport protein. J Med Chem 51:5932–5942
Alnouti Y, Petrick JS, Klaassen CD (2006) Tissue distribution and ontogeny of organic cation transporters in mice. Drug Metab Dispos 34:477–482
Amphoux A, Vialou V, Drescher E, Bruss M, La Mannoury CC, Rochat C et al (2006) Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology 50:941–952
Aoyama N, Takahashi N, Kitaichi K, Ishihara R, Saito S, Maeno N et al (2006) Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder. Alcohol Clin Exp Res 30:1644–1649
Asaka J, Terada T, Tsuda M, Katsura T, Inui K (2007) Identification of essential histidine and cysteine residues of the H+/organic cation antiporter multidrug and toxin extrusion (MATE). Mol Pharmacol 71:1487–1493
Ayrton A, Morgan P (2008) Role of transport proteins in drug discovery and development: a pharmaceutical perspective. Xenobiotica 38:676–708
Bachmakov I, Glaeser H, Fromm MF, König J (2008) Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on OATPs and OCT1. Diabetes 57:1463–1469
Bachmakov I, Glaeser H, Endress B, Morl F, König J, Fromm MF (2009) Interaction of beta-blockers with the renal uptake transporter OCT2. Diabetes Obes Metab 11:1080–1083
Baganz NL, Horton RE, Calderon AS, Owens WA, Munn JL, Watts LT et al (2008) Organic cation transporter 3: keeping the brake on extracellular serotonin in serotonin-transporter-deficient mice. Proc Natl Acad Sci U S A 105:18976–18981
Ballestero MR, Monte MJ, Briz O, Jimenez F, Gonzalez-San MF, Marin JJ (2006) Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps. Biochem Pharmacol 72:729–738
Barendt WM, Wright SH (2002) The human organic cation transporter (hOCT2) recognizes the degree of substrate ionization. J Biol Chem 277:22491–22496
Bayer M, Kuci Z, Schömig E, Gründemann D, Dittmann H, Handgretinger R et al (2009) Uptake of mIBG and catecholamines in noradrenaline- and organic cation transporter-expressing cells: potential use of corticosterone for a preferred uptake in neuroblastoma- and pheochromocytoma cells. Nucl Med Biol 36:287–294
Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH (2009a) Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 58:745–749
Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH (2009b) Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J 9:242–247
Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH (2010) Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genomics 20:38–44
Bednarczyk D, Ekins S, Wikel JH, Wright SH (2003) Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol 63:489–498
Biermann J, Lang D, Gorboulev V, Koepsell H, Sindic A, Schroter R et al (2006) Characterization of regulatory mechanisms and states of human organic cation transporter 2. Am J Physiol Cell Physiol 290:C1521–C1531
Bourdet DL, Pritchard JB, Thakker DR (2005) Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther 315:1288–1297
Boyer JL, Graf J, Meier PJ (1992) Hepatic transport systems regulating pHi, cell volume, and bile secretion. Annu Rev Physiol 54:415–438
Budiman T, Bamberg E, Koepsell H, Nagel G (2000) Mechanism of electrogenic cation transport by the cloned organic cation transporter 2 from rat. J Biol Chem 275:29413–29420
Busch AE, Quester S, Ulzheimer JC, Waldegger S, Gorboulev V, Arndt P et al (1996) Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1. J Biol Chem 271:32599–32604
Busch AE, Karbach U, Miska D, Gorboulev V, Akhoundova A, Volk C et al (1998) Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol 54:342–352
Cetinkaya I, Ciarimboli G, Yalcinkaya G, Mehrens T, Velic A, Hirsch JR et al (2003) Regulation of human organic cation transporter hOCT2 by PKA, PI3K, and calmodulin-dependent kinases. Am J Physiol Renal Physiol 284:F293–F302
Chen Y, Zhang S, Sorani M, Giacomini KM (2007) Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family. J Pharmacol Exp Ther 332:695–700
Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK et al (2009a) Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics 19:497–504
Chen Y, Teranishi K, Li S, Yee SW, Hesselson S, Stryke D et al (2009b) Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J 9:127–136
Cheng Y, Wright SH, Hooth MJ, Sipes IG (2009) Characterization of the disposition and toxicokinetics of N-butylpyridinium chloride in male F-344 rats and female B6C3F1 mice and its transport by organic cation transporter 2. Drug Metab Dispos 37:909–916
Ciarimboli G (2008) Organic cation transporters. Xenobiotica 38:936–971
Ciarimboli G, Struwe K, Arndt P, Gorboulev V, Koepsell H, Schlatter E et al (2004) Regulation of the human organic cation transporter hOCT1. J Cell Physiol 201:420–428
Ciarimboli G, Ludwig T, Lang D, Pavenstädt H, Koepsell H, Piechota HJ et al (2005) Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 167:1477–1484
Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B et al (2010) Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is target for protective interventions. Am J Pathol 176(3):1169–1180
Dresser MJ, Xiao G, Leabman MK, Gray AT, Giacomini KM (2002) Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2). Pharm Res 19:1244–1247
Dudley AJ, Bleasby K, Brown CD (2000) The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. Br J Pharmacol 131:71–79
Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK et al (2008) Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 40:316–321
Feng B, Obach RS, Burstein AH, Clark DJ, de Morais SM, Faessel HM (2008) Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro–in vivo study. Clin Pharmacol Ther 83:567–576
Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A (2009) Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 86:396–402
Fujita T, Urban TJ, Leabman MK, Fujita K, Giacomini KM (2006) Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci 95:25–36
Fukushima-Uesaka H, Maekawa K, Ozawa S, Komamura K, Ueno K, Shibakawa M et al (2004) Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human organic cation transporter (OCT2). Drug Metab Pharmacokinet 19:239–244
Giacomini KM, Sugiyama Y (2006) Membrane transporters and drug response. In: Brunton LL, Lazo JS, Parker RL (eds) Goodman and Gilman’s. The pharmacological basis of therapeutics, 11th edn. McGraw Hill, New York, pp 41–70
Giacomini KM, Hsyu PH, Gisclon LG (1988) Renal transport of drugs: an overview of methodology with application to cimetidine. Pharm Res 5:465–471
Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA et al (2007) The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther 81:328–345
Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S et al (1997) Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 16:871–881
Gorboulev V, Volk C, Arndt P, Akhoundova A, Koepsell H (1999) Selectivity of the polyspecific cation transporter rOCT1 is changed by mutation of aspartate 475 to glutamate. Mol Pharmacol 56:1254–1261
Gorboulev V, Shatskaya N, Volk C, Koepsell H (2005) Subtype-specific affinity for corticosterone of rat organic cation transporters rOCT1 and rOCT2 depends on three amino acids within the substrate binding region. Mol Pharmacol 67:1612–1619
Gorbunov D, Gorboulev V, Shatskaya N, Mueller T, Bamberg E, Friedrich T et al (2008) High-affinity cation binding to organic cation transporter 1 induces movement of helix 11 and blocks transport after mutations in a modelled interaction domain between two helices. Mol Pharmacol 73:50–61
Gründemann D, Schömig E (2000) Gene structures of the human non-neuronal monoamine transporters EMT and OCT2. Hum Genet 106:627–635
Gründemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H (1994) Drug excretion mediated by a new prototype of polyspecific transporter. Nature 372:549–552
Gründemann D, Schechinger B, Rappold GA, Schömig E (1998) Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci 1:349–351
Gründemann D, Liebich G, Kiefer N, Köster S, Schömig E (1999) Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol 56:1–10
Gründemann D, Hahne C, Berkels R, Schomig E (2003) Agmatine is efficiently transported by non-neuronal monoamine transporters extraneuronal monoamine transporter (EMT) and organic cation transporter 2 (OCT2). J Pharmacol Exp Ther 304:810–817
Ha Choi J, Wah Yee S, Kim MJ, Nguyen L, Ho LJ, Kang JO et al (2009) Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1. Pharmacogenet Genomics 19:770–780
Hardman JG, Limbird LE, Gilman AG (eds) (2001) Goodman & Gilman's. The pharmacological basis of therapeutics, 10th edn. New York, McGraw Hill
Harlfinger S, Fork C, Lazar A, Schömig E, Gründemann D (2005) Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol 372:125–130
Hasannejad H, Takeda M, Narikawa S, Huang XL, Enomoto A, Taki K et al (2004) Human organic cation transporter 3 mediates the transport of antiarrhythmic drugs. Eur J Pharmacol 499:45–51
Hayer M, Bönisch H, Brüss M (1999) Molecular cloning, functional characterization and genomic organization of four alternatively spliced isoforms of the human organic cation transporter 1 (hOCT1/SLC22A1). Ann Hum Genet 63:473–482
Hayer-Zillgen M, Brüss M, Bönisch H (2002) Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol 136:829–836
Hesselson SE, Matsson P, Shima JE, Fukushima H, Yee SW, Kobayashi Y et al (2009) Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation. PLoS One 4:e6942
Ho RH, Kim RB (2005) Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78:260–277
Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA et al (2008) Interaction of imatinib with human organic ion carriers. Clin Cancer Res 14:3141–3148
Inazu M, Takeda H, Matsumiya T (2003) Expression and functional characterization of the extraneuronal monoamine transporter in normal human astrocytes. J Neurochem 84:43–52
International HapMap Consortium, Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL et al (2007) A second generation human haplotype map of over 3.1 million SNPs. Nature 449:851–861
Ionita-Laza I, Lange C, Laird M (2009) Estimating the number of unseen variants in the human genome. Proc Natl Acad Sci U S A 106:5008–5013
Ito S, Kusuhara H, Kuroiwa Y, Wu C, Moriyama Y, Inoue K et al (2010) Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine. J Pharmacol Exp Ther 333:341–350
Itoda M, Saito Y, Maekawa K, Hichiya H, Komamura K, Kamakura S et al (2004) Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1). Drug Metab Pharmacokinet 19:308–312
Iwai M, Minematsu T, Narikawa S, Usui T, Kamimura H (2009) Involvement of human organic cation transporter 1 in the hepatic uptake of 1-(2-methoxyethyl)-2-methyl-4, 9-dioxo-3-(pyrazin-2-ylmethyl)-4, 9-dihydro-1H-napht ho[2, 3-d]imidazolium bromide (YM155 monobromide), a novel, small molecule survivin suppressant. Drug Metab Dispos 37:1856–1863
Jonker JW, Wagenaar E, Mol CA, Buitelaar M, Koepsell H, Smit JW et al (2001) Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol Cell Biol 21:5471–5477
Jonker JW, Wagenaar E, Van ES, Schinkel AH (2003) Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol 23:7902–7908
Jung N, Lehmann C, Rubbert A, Knispel M, Hartmann P, van Lunzen J et al (2008) Relevance of the organic cation transporters 1 and 2 for antiretroviral therapy in HIV infection. Drug Metab Dispos 36:1616–1623
Kaiser J (2008) DNA sequencing. A plan to capture human diversity in 1000 genomes. Science 319:395
Kajiwara M, Terada T, Ogasawara K, Iwano J, Katsura T, Fukatsu A et al (2009) Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity. J Hum Genet 54:40–46
Kang HJ, Song IS, Shin HJ, Kim WY, Lee CH, Shim JC et al (2007) Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population. Drug Metab Dispos 35:667–675
Kekuda R, Prasad PD, Wu X, Wang H, Fei YJ, Leibach FH et al (1998) Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J Biol Chem 273:15971–15979
Kerb R (2006) Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 234:4–33
Kerb R, Brinkmann U, Chatskaia N, Gorbunov D, Gorboulev V, Mornhinweg E et al (2002) Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics 12:591–595
Khamdang S, Takeda M, Noshiro R, Narikawa S, Enomoto A, Anzai N et al (2002) Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 303:534–539
Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K et al (2009) Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 15:4750–4758
Kimura H, Takeda M, Narikawa S, Enomoto A, Ichida K, Endou H (2002) Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther 301:293–298
Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T et al (2005a) Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 20:379–386
Kimura N, Okuda M, Inui K (2005b) Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm Res 22:255–259
Kimura N, Masuda S, Katsura T, Inui K (2009) Transport of guanidine compounds by human organic cation transporters, hOCT1 and hOCT2. Biochem Pharmacol 77:1429–1436
Kindla J, Fromm MF, König J (2009) In vitro evidence for the role of OATP and OCT uptake transporters in drug–drug interactions. Expert Opin Drug Metab Toxicol 5:489–500
Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, Eichelbaum M et al (2005) Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 15:861–873
Kobara A, Hiasa M, Matsumoto T, Otsuka M, Omote H, Moriyama Y (2008) A novel variant of mouse MATE-1 H+/organic cation antiporter with a long hydrophobic tail. Arch Biochem Biophys 469:195–199
Koehler MR, Wissinger B, Gorboulev V, Koepsell H, Schmid M (1997) The two human organic cation transporter genes SLC22A1 and SLC22A2 are located on chromosome 6q26. Cytogenet Cell Genet 79:198–200
Koepsell H (1998) Organic cation transporters in intestine, kidney, liver, and brain. Annu Rev Physiol 60:243–266
Koepsell H, Endou H (2004) The SLC22 drug transporter family. Pflugers Arch 447:666–676
Koepsell H, Schmitt BM, Gorboulev V (2003) Organic cation transporters. Rev Physiol Biochem Pharmacol 150:36–90
Koepsell H, Lips K, Volk C (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24:1227–1251
Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4:1073–1081
Lai MY, Jiang FM, Chung CH, Chen HC, Chao PD (1988) Dose dependent effect of cimetidine on procainamide disposition in man. Int J Clin Pharmacol Ther Toxicol 26:118–121
Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H et al (2007) Clustal W and Clustal X version 2.0. Bioinformatics 23:2947–2948
Lazar A, Gründemann D, Berkels R, Taubert D, Zimmermann T, Schömig E (2003) Genetic variability of the extraneuronal monoamine transporter EMT (SLC22A3). J Hum Genet 48:226–230
Lazar A, Zimmermann T, Koch W, Gründemann D, Schömig A, Kastrati A et al (2006) Lower prevalence of the OCT2 Ser270 allele in patients with essential hypertension. Clin Exp Hypertens 28:645–653
Lazar A, Walitza S, Jetter A, Gerlach M, Warnke A, Herpertz-Dahlmann B et al (2008) Novel mutations of the extraneuronal monoamine transporter gene in children and adolescents with obsessive-compulsive disorder. Int J Neuropsychopharmacol 11:35–48
Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE et al (2002) Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 12:395–405
Lee WK, Reichold M, Edemir B, Ciarimboli G, Warth R, Koepsell H et al (2009) Organic cation transporters OCT1, 2, and 3 mediate high-affinity transport of the mutagenic vital dye ethidium in the kidney proximal tubule. Am J Physiol Renal Physiol 296:F1504–F1513
Li Q, Sai Y, Kato Y, Muraoka H, Tamai I, Tsuji A (2004) Transporter-mediated renal handling of nafamostat mesilate. J Pharm Sci 93:262–272
Lips KS, Volk C, Schmitt BM, Pfeil U, Arndt P, Miska D et al (2005) Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium. Am J Respir Cell Mol Biol 33:79–88
Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T et al (2006) Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 17:2127–2135
Matsumoto T, Kanamoto T, Otsuka M, Omote H, Moriyama Y (2008) Role of glutamate residues in substrate recognition by human MATE1 polyspecific H+/organic cation exporter. Am J Physiol Cell Physiol 294:C1074–C1078
Matsushima S, Maeda K, Inoue K, Ohta KY, Yuasa H, Kondo T et al (2009) The inhibition of human multidrug and toxin extrusion 1 is involved in the drug–drug interaction caused by cimetidine. Drug Metab Dispos 37:555–559
Meyer-Wentrup F, Karbach U, Gorboulev V, Arndt P, Koepsell H (1998) Membrane localization of the electrogenic cation transporter rOCT1 in rat liver. Biochem Biophys Res Commun 248:673–678
Minematsu T, Iwai M, Umehara KI, Usui T, Kamimura H (2010) Characterization of human organic cation transporter 1 (OCT1/SLC22A1)-, and OCT2 (SLC22A2)-mediated transport of YM155 monobromide, a novel survivin suppressant. Drug Metab Dispos 38:1–4
Ming X, Ju W, Wu H, Tidwell RR, Hall JE, Thakker DR (2009) Transport of dicationic drugs pentamidine and furamidine by human organic cation transporters. Drug Metab Dispos 37:424–430
Minuesa G, Volk C, Molina-Arcas M, Gorboulev V, Erkizia I, Arndt P et al (2009) Transport of lamivudine (3TC) and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther 329:252–261
Moore KH, Yuen GJ, Raasch RH, Eron JJ, Martin D, Mydlow PK et al (1996) Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin Pharmacol Ther 59:550–558
Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M et al (2002) Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 13:866–874
Müller J, Lips KS, Metzner L, Neubert RH, Koepsell H, Brandsch M (2005) Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol 70:1851–1860
Nagel G, Volk C, Friedrich T, Ulzheimer JC, Bamberg E, Koepsell H (1997) A reevaluation of substrate specificity of the rat cation transporter rOCT1. J Biol Chem 272:31953–31956
Neuhoff S, Ungell AL, Zamora I, Artursson P (2003) pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug–drug interactions. Pharm Res 20:1141–1148
Nies AT, Herrmann E, Brom M, Keppler D (2008) Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). Naunyn Schmiedebergs Arch Pharmacol 376:449–461
Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R et al (2009) Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 50:1227–1240
Nishimura M, Naito S (2005) Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet 20:452–477
Ogasawara K, Terada T, Motohashi H, Asaka J, Aoki M, Katsura T et al (2008) Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney. J Hum Genet 53:607–614
Ohta KY, Inoue K, Hayashi Y, Yuasa H (2006) Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H+ antiporter in the kidney. Drug Metab Dispos 34:1868–1874
Okabe M, Szakacs G, Reimers MA, Suzuki T, Hall MD, Abe T et al (2008) Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther 7:3081–3091
Okuda M, Kimura N, Inui K (2006) Interactions of fluoroquinolone antibacterials, DX-619 and levofloxacin, with creatinine transport by renal organic cation transporter hOCT2. Drug Metab Pharmacokinet 21:432–436
Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y (2005) A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A 102:17923–17928
Popp C, Gorboulev V, Muller TD, Gorbunov D, Shatskaya N, Koepsell H (2005) Amino acids critical for substrate affinity of rat organic cation transporter 1 line the substrate binding region in a model derived from the tertiary structure of lactose permease. Mol Pharmacol 67:1600–1611
Ramensky V, Bork P, Sunyaev S (2002) Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30:3894–3900
Sakata T, Anzai N, Shin HJ, Noshiro R, Hirata T, Yokoyama H et al (2004) Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem Biophys Res Commun 313:789–793
Sata R, Ohtani H, Tsujimoto M, Murakami H, Koyabu N, Nakamura T et al (2005) Functional analysis of organic cation transporter 3 expressed in human placenta. J Pharmacol Exp Ther 315:888–895
Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM et al (2001) Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 358:383–384
Schmitt BM, Koepsell H (2005) Alkali cation binding and permeation in the rat organic cation transporter rOCT2. J Biol Chem 280:24481–24490
Schmitt A, Mossner R, Gossmann A, Fischer IG, Gorboulev V, Murphy DL et al (2003) Organic cation transporter capable of transporting serotonin is up-regulated in serotonin transporter-deficient mice. J Neurosci Res 71:701–709
Schmitt BM, Gorbunov D, Schlachtbauer P, Egenberger B, Gorboulev V, Wischmeyer E et al (2009) Charge-to-substrate ratio during organic cation uptake by rat OCT2 is voltage dependent and altered by exchange of glutamate 448 with glutamine. Am J Physiol Renal Physiol 296:F709–F722
Shikata E, Yamamoto R, Takane H, Shigemasa C, Ikeda T, Otsubo K et al (2007) Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet 52:117–122
Shnitsar V, Eckardt R, Gupta S, Grottker J, Muller GA, Koepsell H et al (2009) Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res 69:1494–1501
Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Stryke D et al (2003) Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci U S A 100:5902–5907
Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA et al (2007) Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 117:1422–1431
Shu Y, Brown C, Castro R, Shi R, Lin E, Owen R et al (2008) Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 83:273–280
Siva N (2008) 1000 Genomes project. Nat Biotechnol 26:256
Somogyi A, Stockley C, Keal J, Rolan P, Bochner F (1987) Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 23:545–551
Song I, Shin H, Shim E, Jung I, Kim W, Shon J et al (2008) Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther 84:559–562
Sturm A, Gorboulev V, Gorbunov D, Keller T, Volk C, Schmitt BM et al (2007) Identification of cysteines in rat organic cation transporters rOCT1 (C322, C451) and rOCT2 (C451) critical for transport activity and substrate affinity. Am J Physiol Renal Physiol 293:F767–F779
Suhre WM, Ekins S, Chang C, Swaan PW, Wright SH (2005) Molecular determinants of substrate/inhibitor binding to the human and rabbit renal organic cation transporters hOCT2 and rbOCT2. Mol Pharmacol 67:1067–1077
Tachampa K, Takeda M, Khamdang S, Noshiro-Kofuji R, Tsuda M, Jariyawat S et al (2008) Interactions of organic anion transporters and organic cation transporters with mycotoxins. J Pharmacol Sci 106:435–443
Tahara H, Kusuhara H, Endou H, Koepsell H, Imaoka T, Fuse E et al (2005) A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther 315:337–345
Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T et al (2002) Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther 300:918–924
Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, Inui K (2007) Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol 74:359–371
Tanihara Y, Masuda S, Katsura T, Inui KI (2009) Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. Biochem Pharmacol 78:1263–1271
Taubert D, Grimberg G, Stenzel W, Schömig E (2007) Identification of the endogenous key substrates of the human organic cation transporter OCT2 and their implication in function of dopaminergic neurons. PLoS One 2:e385
Terada T, Inui KI (2008) Physiological and pharmacokinetic roles of H(+)/organic cation antiporters (MATE/SLC47A). Biochem Pharmacol 75:1689–1696
Terada T, Masuda S, Asaka J, Tsuda M, Katsura T, Inui K (2006) Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. Pharm Res 23:1696–1701
Thomas J, Wang L, Clark RE, Pirmohamed M (2004) Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104:3739–3745
Tregouet DA, Konig IR, Erdmann J, Munteanu A, Braund PS, Hall AS et al (2009) Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 41:283–285
Tsuda M, Terada T, Mizuno T, Katsura T, Shimakura J, Inui KI (2009a) Targeted disruption of the multidrug and toxin extrusion 1 (Mate1) gene in mice reduces renal secretion of metformin. Mol Pharmacol 75:1280–1286
Tsuda M, Terada T, Ueba M, Sato T, Masuda S, Katsura T et al (2009b) Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther 329:185–191
Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D et al (2009) The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 86:299–306
Umehara KI, Iwatsubo T, Noguchi K, Usui T, Kamimura H (2008) Effect of cationic drugs on the transporting activity of human and rat OCT/Oct 1–3 in vitro and implications for drug–drug interactions. Xenobiotica 38:1203–1218
Urakami Y, Kimura N, Okuda M, Inui K (2004) Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res 21:976–981
van Crugten J, Bochner F, Keal J, Somogyi A (1986) Selectivity of the cimetidine-induced alterations in the renal handling of organic substrates in humans. Studies with anionic, cationic and zwitterionic drugs. J Pharmacol Exp Ther 236:481–487
van Montfoort JE, Muller M, Groothuis GM, Meijer DK, Koepsell H, Meier PJ (2001) Comparison of “type I” and “type II” organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther 298:110–115
Verhaagh S, Schweifer N, Barlow DP, Zwart R (1999) Cloning of the mouse and human solute carrier 22a3 (Slc22a3/SLC22A3) identifies a conserved cluster of three organic cation transporters on mouse chromosome 17 and human 6q26–q27. Genomics 55:209–218
Vialou V, Amphoux A, Zwart R, Giros B, Gautron S (2004) Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation. J Neurosci 24:2846–2851
Vialou V, Balasse L, Callebert J, Launay JM, Giros B, Gautron S (2008) Altered aminergic neurotransmission in the brain of organic cation transporter 3-deficient mice. J Neurochem 106:1471–1482
Volk C, Gorboulev V, Kotzsch A, Muller TD, Koepsell H (2009) Five amino acids in the innermost cavity of the substrate binding cleft of organic cation transporter 1 interact with extracellular and intracellular corticosterone. Mol Pharmacol 76:275–289
Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y (2002) Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 302:510–515
Wang DS, Kusuhara H, Kato Y, Jonker JW, Schinkel AH, Sugiyama Y (2003) Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol 63:844–848
Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE (2008a) Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 83:258–264
Wang ZJ, Yin OQ, Tomlinson B, Chow MS (2008b) OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics 18:637–645
White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC et al (2006) OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108:697–704
White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S et al (2007) Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110:4064–4072
Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway S et al (2000) Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol 279:F449–F458
Wultsch T, Grimberg G, Schmitt A, Painsipp E, Wetzstein H, Breitenkamp AF et al (2009) Decreased anxiety in mice lacking the organic cation transporter 3. J Neural Transm 116:689–697
Yokoo S, Masuda S, Yonezawa A, Terada T, Katsura T, Inui KI (2008) Significance of OCT3/SLC22A3, organic cation transporter 3, expression for the cytotoxic effect of oxaliplatin in colorectal cancer. Drug Metab Dispos 36:2299–2306
Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui KI (2006) Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and MATE family). J Pharmacol Exp Ther 319:879–886
Zach O, Krieger O, Foedermayr M, Zellhofer B, Lutz D (2008) OCT1 (SLC22A1) R61C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients. Leuk Lymphoma 49:2222–2223
Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM (1997) Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol 51:913–921
Zhang L, Schaner ME, Giacomini KM (1998) Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther 286:354–361
Zhang L, Gorset W, Washington CB, Blaschke TF, Kroetz DL, Giacomini KM (2000) Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metab Dispos 28:329–334
Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A et al (2006) Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 66:8847–8857
Zhang X, Cherrington NJ, Wright SH (2007) Molecular identification and functional characterization of rabbit MATE1 and MATE2-K. Am J Physiol Renal Physiol 293:F360–F370
Zhou K, Donnelly LA, Kimber CH, Donnan PT, Doney AS, Leese G et al (2009) Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes 58:1434–1439
Zolk O, Solbach TF, König J, Fromm MF (2008) Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2). Naunyn Schmiedebergs Arch Pharmacol 379:337–348
Zolk O, Solbach TF, König J, Fromm MF (2009) Functional characterization of the human organic cation transporter 2 variant p. 270Ala>Ser. Drug Metab Dispos 37:1312–1318
Zwart R, Verhaagh S, Buitelaar M, Popp-Snijders C, Barlow DP (2001) Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice. Mol Cell Biol 21:4188–4196
Acknowledgments
The authors’ work on the importance of transporters in drug therapy is supported by the Robert-Bosch Foundation Stuttgart, the IZEPHA Grants #6-0-0/672 and #8-0-0/674, the Federal Ministry for Education and Research (BMBF, Berlin, Germany) grant 03 IS 2061C, the German Research Foundation Grant SFB487/A4, and the Deutsche Krebshilfe (grant 107150). We thank Dr. Elke Schaeffeler for helpful discussions.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Berlin Heidelberg
About this chapter
Cite this chapter
Nies, A.T., Koepsell, H., Damme, K., Schwab, M. (2011). Organic Cation Transporters (OCTs, MATEs), In Vitro and In Vivo Evidence for the Importance in Drug Therapy. In: Fromm, M., Kim, R. (eds) Drug Transporters. Handbook of Experimental Pharmacology, vol 201. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-14541-4_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-14541-4_3
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-14540-7
Online ISBN: 978-3-642-14541-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)